Serán Bioscience's Expansion Strategy
Serán Bioscience, a leading contract development and manufacturing organization (CDMO), is embarking on an exciting journey of growth with a significant strategic investment of over $200 million. This endeavor is made possible through collaboration with Bain Capital Life Sciences, which is spearheading the initiative. Additionally, existing investor Vivo Capital continues to play an essential role, solidifying a strong partnership focused on propelling Serán’s growth objectives.
Boosting Manufacturing Capacity
The funding provided by Bain Capital will primarily go towards constructing a new commercial-scale manufacturing facility. This state-of-the-art site is expected to enhance Serán’s ability to deliver integrated services across the entire drug delivery spectrum. Ranging from the initial stages of development to commercial production, this facility will significantly improve the company's capabilities, allowing it to compete more effectively in the biotechnology sector.
Highlights of the New Facility
Slated for completion around 2026, this facility will focus on various drug delivery modalities that cater to Serán’s clients' diverse needs. It will incorporate cutting-edge technologies like spray drying, hot melt extrusion, and nano-milling, positioning Serán at the forefront of innovative drug delivery solutions. In addition, the facility will have significant finished dose capabilities, including granulation, tableting, coating, and encapsulation, ensuring it meets the stringent requirements of the pharmaceutical industry.
Building Partnerships for Achievements
Dan Smithey, Co-Founder and CEO of Serán, expressed immense pride in the partnership with Bain Capital. He believes this collaboration will dramatically enhance Serán's clinical manufacturing capabilities, thereby effectively supporting the market introduction of new medicines. Smithey highlighted their shared ambition to further expand Serán’s expertise in science-based drug development.
Dedication to Innovation
Bain Capital’s Managing Director Will Cozean reiterated the commitment to innovation, emphasizing Serán's strategic position to capitalize on long-term growth trends in drug delivery technologies. By focusing on next-generation oral medications, the company shows foresight in tackling the evolving challenges facing the market.
The Role of Vivo Capital
Vivo Capital’s involvement represents confidence in Serán's future. Managing Partner Gaurav Aggarwal emphasized the impressive accomplishments of Serán's team and their commitment to advancing commercial-scale projects that support pharmaceutical innovators. As Serán plans to expand its hiring efforts, the growth of this facility will help create a nearly 200,000-square-foot campus.
About Serán Bioscience
Serán is dedicated to providing a wide range of development, analytical, and manufacturing services specifically designed for pharmaceutical and biotechnology companies. With a solid foundation in physics, chemistry, and engineering principles, Serán excels at developing robust formulations. Their skilled team is proficient in various manufacturing processes, including spray drying and melt extrusion, making the company a trustworthy partner in the development of complex pharmaceutical products.
About Bain Capital Life Sciences
Bain Capital Life Sciences, established in 2016, is recognized for its strong investment strategies in healthcare and life sciences. With a rich background and a focus on biopharmaceuticals and medical innovations, this firm plays a crucial role in enhancing the capabilities of companies like Serán. Their expertise in investing across key phases of value creation makes them a valuable partner in bolstering clinical and commercial efforts.
About Vivo Capital
Founded in 1996, Vivo Capital is an influential global investment firm, primarily focused on healthcare. Their diverse investment strategy includes venture capital, growth equity, and public equities, showcasing their strategic approach across various healthcare sectors. Vivo Capital’s extensive investment portfolio and significant assets under management enhance its standing as a leading player in the industry.
Frequently Asked Questions
What is the purpose of the $200 million investment?
This investment aims to construct a new commercial-scale manufacturing facility, supporting Serán's growth and expanding its service offerings.
When will the new facility be completed?
The timeline for the construction of the new facility suggests it will be completed by 2026, increasing Serán’s manufacturing capabilities.
Who are the main investors backing Serán's growth?
The primary investors in this strategic growth initiative are Bain Capital Life Sciences and existing investor Vivo Capital.
What services will the new facility provide?
The facility is expected to offer services related to various drug delivery modalities, including oral, pulmonary, and nasal delivery, utilizing advanced manufacturing technologies.
How many employees does Serán plan to hire for this expansion?
As part of this expansion, Serán plans to hire up to 150 additional employees to enhance its operational capabilities as the new facility develops.
